These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 1700231)
1. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype. Momparler RL; Onetto-Pothier N; Momparler LF Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Momparler RL; Momparler LF; Samson J Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL; Côté S; Eliopoulos N Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076 [TBL] [Abstract][Full Text] [Related]
4. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine. Momparler RL; Momparler LF; Samson J Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115 [TBL] [Abstract][Full Text] [Related]
5. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Momparler RL; Bouchard J; Samson J Leuk Res; 1985; 9(11):1361-6. PubMed ID: 2417065 [TBL] [Abstract][Full Text] [Related]
6. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine. Momparler RL; Laliberté J Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182 [TBL] [Abstract][Full Text] [Related]
9. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Bouffard DY; Momparler LF; Momparler RL Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212 [TBL] [Abstract][Full Text] [Related]
11. Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. Doré BT; Momparler RL Anticancer Drugs; 1992 Jun; 3(3):281-7. PubMed ID: 1381972 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL; Côté S; Eliopoulos N Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684 [TBL] [Abstract][Full Text] [Related]
13. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552 [TBL] [Abstract][Full Text] [Related]
14. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Kong XB; Tong WP; Chou TC Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine. Momparler RL; Momparler LF Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188 [TBL] [Abstract][Full Text] [Related]
17. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase. Momparler RL; Doré BT; Labiberté J; Momparler LF Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Côté S; Momparler RL Anticancer Drugs; 1993 Jun; 4(3):327-33. PubMed ID: 7689364 [TBL] [Abstract][Full Text] [Related]
19. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Eliopoulos N; Cournoyer D; Momparler RL Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951 [TBL] [Abstract][Full Text] [Related]
20. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Laliberté J; Marquez VE; Momparler RL Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]